Study of IMRT Radiotherapy Concurrent Chemothrerapy for Anal Cancer

Phase II Study of IMRT Radiotherapy Concurrent Chemothrerapy for Anal Cancer

The purpose of this study is to evaluate the efficacy and adverse events of intensity modulated radiation therapy (IMRT) concurrent with chemotherapy for anal squamous carcinoma. All enrolled anal squamous carcinoma patients are intented to receive IMRT concurrent with Capecitabine + mitomycin ± cetuximab targeted therapy.

Inclusion Criteria:

• CT/MRI diagnosed stage cT1-4N0-3;
• Histologically confirmed anal squamous carcinoma;
• KPS >= 70
• Adequate organ function;
• No previous radiotherapy or chemotherapy;
• No surgery.

Exclusion Criteria:

• Previous malignant cancer history;
• Allegic to 5-fu or MMC